ACCEL Lite: Late Breaker: APOLLO Trial - Magnitude And Duration Of Effects Of A Short-interfering RNA Targeting Lipoprotein(a)

In this interview, Steven E. Nissen, MD, MACC and Anthony N. DeMaria MD, MACC, with Anum Saeed MD, discuss the ACC.22 Late Breaker: Magnitude and Duration of Effects of a Short-interfering RNA Targeting Lipoprotein(a): A Placebo-controlled Double-blind Dose-ranging Trial.

Related References:

  1. Nissen SE, Wolski K, Balog C, et al. Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. JAMA. Published online April 03, 2022. doi:10.1001/jama.2022.5050

Clinical Topics: Dyslipidemia, Advanced Lipid Testing, Lipid Metabolism, Congenital Heart Disease and Pediatric Cardiology, Prevention

Keywords: ACCELLite, RNA, Lipoprotein(a)

< Back to Listings